Promising Alzheimer’s Drug Demonstrates Slowed Progression in Patients; U.S. Approval on the Horizon, Anticipated
Another experimental Alzheimer’s drug, donanemab, has been found to modestly slow the progression of the disease in patients by about four to seven months, according to researchers. Eli Lilly and …